CTI BioPharma Corp. (CTIC)

0.79
0.03 3.33
NASDAQ : Health Technology
Prev Close 0.82
Open 0.80
Day Low/High 0.79 / 0.82
52 Wk Low/High 0.60 / 2.04
Volume 80.48K
Avg Volume 132.80K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 45.86M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Biotech Stock Mailbag: Generex

Columnist Feuerstein talks about alternative insulin-delivery devices and answers readers' questions about Generex and other biotech firms.

Robbins Umeda LLP Announces Investigation Of Cell Therapeutics, Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by certain officers and directors of Cell Therapeutics, Inc.

Kendall Law Group Plans Class Action On Behalf Of Cell Therapeutics, Inc. Shareholders

Kendall Law Group announced today that it plans to join a lawsuit on behalf of shareholders of Cell Therapeutics, Inc.

Law Offices Of Howard G. Smith Announces Class Action Lawsuit Against Cell Therapeutics, Inc.

Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the common stock of Cell Therapeutics, Inc.

Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Cell Therapeutics, Inc.

In second graf, third sentence the link should read http://www.

Holzer Holzer & Fistel, LLC Is Investigating Potential Violations Of Federal Securities Laws By Cell Therapeutics, Inc.

Holzer Holzer & Fistel, LLC is investigating potential violations of the federal securities laws by Cell Therapeutics, Inc.

10 Biotech Stocks On the Line

Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.

Cell Therapeutics, Zoom Technologies: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Medivation: Biotech Stock Mailbag

Medivation's (MDVN) Alzheimer's drug, Dimebon, failed an important drug trial. Hard lessons were learned, as explained in this bonus Mailbag.

New FDA Date for Cell Therapeutics: BioBuzz

New FDA Date for Cell Therapeutics: BioBuzz

FDA will reconvene advisory panel on March 22, while Cell Therapeutics highlights debt and drug problems in its annual report.

Uh Oh, Opaxio!: BioBuzz

Prospects fade for Cell Therapeutics' ovarian cancer drug following positive results from a competitor.

Biotech Stock Mailbag: Rexahn Pharma

In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.

10 Biotech Stocks Facing FDA Approval

News about FDA drug approvals and rejections can send biotech stocks rocketing or plummeting. Here are ten companies facing FDA approval decisions this year.

5 Dumbest Things on Wall Street: Feb. 12

5 Dumbest Things on Wall Street: Feb. 12

Schwartz signs off; Toyota's latest letdown; CIT's 'new' boss; Cell Therapeutics needs therapy; and Greek tax cheats.

Five Dumbest Things on Wall Street: Feb. 12

Schwartz signs off; Toyota's latest letdown; CIT's 'new' boss; Cell Therapeutics needs therapy; and Greek tax cheats.

Biotech Stock Mailbag: NexMed

Biotech Stock Mailbag: NexMed

Biotech watchdog Adam Feuerstein answers readers' questions about NexMed, Cell Therapeutics and other news-worthy stocks.

Blizzard Blitzes Markets

Blizzard Blitzes Markets

The blizzard across the East Coast of the U.S. pelts the capital markets.

FDA Tough on Cell Therapeutics' Drug

Investors were warned last week about problems with Cell Therapeutics' cancer drug pixantrone.

Irvine Sensors, National Bank of Greece: Early Volume Plays

Irvine Sensors, National Bank of Greece: Early Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

FDA Raises Concerns About Cell Therapeutics' Cancer Drug

FDA Raises Concerns About Cell Therapeutics' Cancer Drug

Ahead of a Feb. 10 advisory panel meeting, regulators say pivotal trial of pixantrone was too small; they also express concern about heart safety of drug.

Biotech Stock Mailbag: Soligenix

Our biotech columnist answers readers' burning questions about Soligenix, Cell Therapeutics, and other biotech stocks.

Biotech Calendar: Key Dates for February

Biotech Calendar: Key Dates for February

February's list of important, potentially stock-moving biotech events.

Cell Therapeutics' Upcoming FDA Worries

If the FDA has problems with Cell Therapeutics' cancer drug pixantrone on Feb. 10, here are the likely hot spots.

GenVec Financing Sinks Shares: BioBuzz

Offering comes right before data read-out from a crucial cancer drug trial.

Biotech Stock Mailbag: Adventrx Pharmaceuticals

Biotech Stock Mailbag: Adventrx Pharmaceuticals

Fresh from the J.P. Morgan Healthcare Conference in San Francisco, columnist Adam Feuerstein answers readers' questions about hot-topic stocks.

Cell Therapeutics Has Strange Timing

Cell Therapeutics has raised $30 million just a month prior to an important Food and Drug Administration meeting on its lymphoma drug pixantrone.

EnteroMedics, Bionovo: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.

Jackson Hewitt, Cell Therapeutics: Late Day Volume Plays

Jackson Hewitt, Cell Therapeutics: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Wednesday's session.

Biotech Stock Mailbag: Novelos Therapeutics

Biotech columnist Adam Feuerstein rolls out the year's first Mailbag, answering questions about Novelos and other stocks.

Cell Therapeutics Adopts 'poison Pill' Plan

Cell Therapeutics moves to deter takeover as it waits for FDA panel vote on cancer drug

TheStreet Quant Rating: D (Sell)